Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market

Contributed by: Business Wire

Tags

Biotechnology
General Health
Mental Health
Health
Pharmaceutical
Avadel Pharmaceuticals plc

More Like This

PR Newswire associated0

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

PR Newswire associated0

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

PR Newswire associated0

Alkermes Response to Avadel Announcement

PR Newswire associated0

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

PR Newswire associated0

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences